COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

Search

Novo Nordisk A-S (Class B)

Slēgts

473.9 -1.61

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

473.7

Max

475.85

Galvenie mērījumi

By Trading Economics

Ienākumi

929M

28B

Pārdošana

14B

86B

P/E

Sektora vidējais

23.043

73.239

EPS

6.34

Dividenžu ienesīgums

3.03

Peļņas marža

32.947

Darbinieki

76,302

EBITDA

4.1B

39B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+9.53% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.03%

3.06%

Nākamie ieņēmumi

2025. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

231B

2.3T

Iepriekšējā atvēršanas cena

475.51

Iepriekšējā slēgšanas cena

473.9

Novo Nordisk A-S (Class B) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 25. febr. 15:33 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

2025. g. 5. febr. 11:53 UTC

Peļņas

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

2025. g. 5. febr. 08:19 UTC

Peļņas

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

2025. g. 28. marts 15:11 UTC

Tirgus saruna

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

2025. g. 27. marts 13:45 UTC

Tirgus saruna
Peļņas

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

2025. g. 24. marts 10:19 UTC

Tirgus saruna

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

2025. g. 24. marts 09:08 UTC

Tirgus saruna
Peļņas

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

2025. g. 19. marts 15:54 UTC

Top Ziņas

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

2025. g. 11. marts 15:31 UTC

Tirgus saruna

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

2025. g. 11. marts 14:58 UTC

Tirgus saruna

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 10. febr. 12:00 UTC

Top Ziņas

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

2025. g. 7. febr. 10:30 UTC

Top Ziņas

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

2025. g. 6. febr. 16:16 UTC

Top Ziņas
Peļņas

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

2025. g. 6. febr. 14:56 UTC

Peļņas

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

2025. g. 5. febr. 13:59 UTC

Peļņas

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

2025. g. 5. febr. 12:02 UTC

Peļņas

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

2025. g. 5. febr. 11:35 UTC

Tirgus saruna
Peļņas

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

2025. g. 5. febr. 10:10 UTC

Karstas akcijas

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

2025. g. 5. febr. 09:43 UTC

Peļņas

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

2025. g. 5. febr. 08:47 UTC

Tirgus saruna
Peļņas

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

2025. g. 5. febr. 08:38 UTC

Tirgus saruna
Peļņas

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

2025. g. 5. febr. 08:32 UTC

Peļņas

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

2025. g. 5. febr. 08:30 UTC

Tirgus saruna
Peļņas

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

2025. g. 5. febr. 06:46 UTC

Peļņas

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

2025. g. 5. febr. 06:45 UTC

Peļņas

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

2025. g. 5. febr. 06:43 UTC

Peļņas

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

2025. g. 5. febr. 06:42 UTC

Peļņas

Novo Nordisk: 2025 Capex Expected to be Around DKK65B, Reflecting Expansion of Global Supply Chain

2025. g. 5. febr. 06:39 UTC

Peļņas

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints and Related Drug Shortage Notifications

2025. g. 5. febr. 06:39 UTC

Peļņas

Novo Nordisk: Sales Growth Positively Impacted by Gross-to-Net Adjustments in U.S.

Salīdzinājums

Cenas izmaiņa

Novo Nordisk A-S (Class B) Prognoze

Cenas mērķis

By TipRanks

9.53% augšup

Prognoze 12 mēnešiem

Vidējais 1,162.73 DKK  9.53%

Augstākais 1,550 DKK

Zemākais 720 DKK

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Novo Nordisk A-S (Class B) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

2

Turēt

2

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.